China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has presented new data from a pooled safety and efficacy analysis of DZD8586, a non-covalent blood-brain barrier (BBB) penetrant dual inhibitor targeting LYN and BTK, in patients with B-cell non-Hodgkin lymphoma (B-NHL) at the 66th American Society of Hematology (ASH) Annual Meeting.
Clinical Study Overview
The analysis compiled data from ongoing Phase I/II clinical studies assessing DZD8586 in B-NHL patients who had either progressed after or were intolerant to previous systemic therapies. In the subgroup of chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL), the overall response rate (ORR) was reported at 57.9% for patients receiving doses of 50 mg or more.
Efficacy Against Resistance Mutations
Tumor responses were noted in patients previously treated with both covalent and non-covalent BTK inhibitors (BTKi) and Bcl-2 inhibitors. Notably, tumor responses were observed in patients harboring classic BTK resistance mutations (C481X) as well as “dead” mutations. Preliminary anti-tumor activity was also recorded in patients pre-treated with pirtobrutinib, specifically those with the T474I mutation.
Conclusion
Dizal Pharmaceutical’s DZD8586 is showing promise in treating challenging cases of B-NHL, particularly in patients with resistance to existing therapies. The findings presented at the ASH Annual Meeting underscore the potential of this innovative dual inhibitor in enhancing treatment options for B-cell malignancies.-Fineline Info & Tech
